corticotropin-releasing hormone

(redirected from Corticotrophin-releasing factor)
Also found in: Dictionary, Medical.

corticotropin-releasing hormone

[‚kȯrd·ə·kō′trō·pən ri¦lēs·iŋ ‚hȯr‚mōn]
(biochemistry)
A substance produced by the hypothalamus that stimulates the pituitary gland to produce adrenocorticotropic hormone (ACTH). Abbreviated CRH.
Mentioned in ?
References in periodicals archive ?
The stress hormone, corticotrophin-releasing factor (CRF), was found to be raised threefold in both single stress models, albeit the effect of NMS was not statistically significant (p = 0.
Antagonism of corticotrophin-releasing factor attenuates the enhanced responsiveness to stress observed during protracted ethanol abstinence.
Neuroanotomical evidence for reciprocal regulation of the corticotrophin-releasing factor and oxytocin systems in the hypothalamus and the bed nucleus of the stria terminalis of the rat: implications for balancing stress and affect.
With age, mice produced a stress hormone called corticotrophin-releasing factor, or CRF that is associated with hair loss.
In addition, researchers are evaluating the therapeutic potential of corticotrophin-releasing factor antagonists and neurokinin 1 antagonists, which may address the relationship between stress and alcohol consumption.
Pathways involved in gut mucosal barrier dysfunction induced in adult rats by maternal deprivation: corticotrophin-releasing factor and nerve growth factor interplay.
Biological changes observed include increased corticotrophin-releasing factor concentrations, catecholamine depletion within the central nervous system, and reduced hippocampal volume.
Human umbilical vein endothelial cells: a new source and potential target for corticotrophin-releasing factor.
Early post-natal experience alters hypothalamic corticotrophin-releasing factor mRNA, median eminence CRF content and stress induced release in adults.
Nasdaq:NBIX) Thursday announced that its scientists presented data which further validates corticotrophin-releasing factor (CRF) for anxiety/depression at the Society for Neuroscience meeting held this week in New Orleans.
b) Treatment with STW5 protected against the rise in plasma levels of corticotrophin-releasing factor and corticosterone